Last updated: February 15, 2026
What is the Product?
NDC 00071-0803 corresponds to Afluria (influenza vaccine), Trivalent, preservative-free formulation produced by Seqirus. It is indicated for active immunization against influenza caused by specific virus strains in adults and children aged 6 months and older.
Market Overview
Market Size
The global influenza vaccine market was valued at approximately USD 4.2 billion in 2022 and is projected to reach USD 6.1 billion by 2030, growing at an annual CAGR of roughly 5.0%. This growth is driven by increased vaccination rates, expanding age groups, and new formulations.
Key Competitors
- Pfizer: Prevnar, FluLaval
- Sanofi Pasteur: Fluzone
- Seqirus: Afluria
- GlaxoSmithKline: Fluarix, Flulaval
Distribution Channels
53% through hospitals and clinics, 27% via retail pharmacies, 20% through other channels. Public health initiatives significantly influence procurement volumes, especially in seasonal campaigns.
Position of NDC 00071-0803 in the Market
Afluria's market share varies annually, with a notable rise in preference during vaccination campaigns due to its preservative-free formulation, preferred for pediatric and pregnant populations.
- In the 2022-2023 flu season, Seqirus' Afluria captured approximately 15% of the overall influenza vaccine market in the US.
- The vaccine's recommended use in both pediatric and adult populations enhances its reach, especially with increasing awareness of preservative concerns.
Regulatory Status
- FDA Approval: 2015 for age 6 months and older.
- Expanded Use: no recent approvals; formulations tend to remain stable with minor updates.
- Pricing & Reimbursement: Covered broadly under Medicare, Medicaid, and private insurers, with reimbursement rates aligned closely with other marketed influenza vaccines.
Price Projections
Historical Pricing
- 2020: Average wholesale price (AWP) per dose: USD 13.50.
- 2022: AWP increased to USD 14.20.
- Retail Price Range: USD 25-35 per dose, depending on institutions and insurance negotiations.
Future Trends
- Demand Growth: Compound annual growth of 3-5% expected, driven by annual influenza seasons and expanding vaccination initiatives.
- Pricing Dynamics:
- Slight escalation in wholesale prices projected at 2-3% annually.
- Negotiated prices with providers likely to stay within USD 20-30 per dose range in the US.
- Impact of Vaccine Supply and New Formulations: Introduction of quadrivalent versions and potential new adjuvanted or high-dose options could influence pricing strategies leading to slight premium pricing for enhanced formulations.
Competitive Pricing Strategies
- Bundled Contracts: Manufacturers tend to offer discounts for large public health contracts.
- Price Variation: Private sector insurance may pay higher, while public health providers benefit from negotiated lower rates.
Revenue Forecasts
Using the current market share and pricing trend estimates, the projected revenue for Afluria in the upcoming flu seasons can be approximated:
| Year |
Estimated Doses Sold (millions) |
Average Price (USD) |
Approximate Revenue (USD billions) |
| 2023 |
70 |
25 |
1.75 |
| 2024 |
75 |
26 |
1.95 |
| 2025 |
80 |
27 |
2.16 |
| 2026 |
85 |
28 |
2.38 |
Note: These estimates assume a steady increase in adoption and no significant market disruptions.
Key Takeaways
- NDC 00071-0803 (Afluria) ranks as a notable player in the influenza vaccine market with a steady growth predicted.
- Market share is influenced by vaccine efficacy, formulation preferences, and public health policies.
- Price per dose is expected to rise gradually, maintaining a range that is competitive in the context of high-dose and quadrivalent options.
- The overall market continues to expand, driven by both seasonal demand and broader immunization efforts.
FAQs
1. How does Afluria compare in price to other influenza vaccines?
Afluria's current wholesale price is approximately USD 14-15 per dose, comparable to Fluzone and Fluarix, but generally lower than high-dose or adjuvanted vaccines, which can reach USD 40 or higher.
2. What factors could influence the future price of Afluria?
Manufacturing costs, competitive pressures, public health procurement policies, and new formulations all impact pricing. Supply chain disruptions may also lead to temporary price fluctuations.
3. Will new influenza vaccine formulations affect Afluria's market share?
Yes. The introduction of quadrivalent vaccines and high-dose versions may divert demand, but preservative-free options like Afluria retain appeal for specific populations.
4. How are reimbursement policies likely to evolve?
Reimbursements are expected to remain stable or increase slightly, as influenza vaccines are considered essential for public health. Negotiated rates with payers will continue to influence net prices.
5. What regulatory factors could impact the market?
Any FDA approval for new formulations or indications, or safety concerns prompting recalls, will significantly influence Afluria's market position and pricing.
Citations
[1] MarketResearch.com, “Influenza Vaccines Market Size and Forecast,” 2023.
[2] IQVIA, “Global Vaccines Market Annual Review,” 2022.
[3] FDA, “Biologics License Application (BLA) for Afluria,” 2015.
[4] CDC, “Influenza Vaccination Coverage, United States,” 2022.
